MX2012013613A - Eficacia superior de anticuerpos cd37 en muestras de sangre de cll. - Google Patents

Eficacia superior de anticuerpos cd37 en muestras de sangre de cll.

Info

Publication number
MX2012013613A
MX2012013613A MX2012013613A MX2012013613A MX2012013613A MX 2012013613 A MX2012013613 A MX 2012013613A MX 2012013613 A MX2012013613 A MX 2012013613A MX 2012013613 A MX2012013613 A MX 2012013613A MX 2012013613 A MX2012013613 A MX 2012013613A
Authority
MX
Mexico
Prior art keywords
patients
treatment
antibodies
risk
cll
Prior art date
Application number
MX2012013613A
Other languages
English (en)
Other versions
MX341463B (es
Inventor
Karl-Heinz Heider
Stilgenbauer Stephan
Zenz Thorsten
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44546328&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2012013613(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MX2012013613A publication Critical patent/MX2012013613A/es
Publication of MX341463B publication Critical patent/MX341463B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención describe anticuerpos CD37, especialmente A2 y B2, para el tratamiento de pacientes con CLL, especialmente de pacientes que pertenecen a un grupo de pacientes de "alto riesgo" o "ultra-alto riesgo". Estos pacientes son pacientes refractarios al tratamiento con fludarabina o bien pacientes que portan un marcador genético que indica un pronóstico deficiente o un riesgo incrementado de fracaso de tratamiento, por ejemplo, pacientes con disfunción de TP53 o deleción del cromosoma 17p13, o pacientes después del fracaso a tratamiento anti-CD20 anterior. La habilidad de A2 y B2 para la depleción de células de CLL es alta en muestras de pacientes derivadas de pacientes con riesgo normal y con riesgo incrementado (pacientes de "alto riesgo") y claramente superior a la de rituximab y alemtuzumab.
MX2012013613A 2010-07-16 2011-07-15 Eficacia superior de anticuerpos cd37 en muestras de sangre de cll. MX341463B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10169795 2010-07-16
EP10175586 2010-09-07
PCT/EP2011/062133 WO2012007576A1 (en) 2010-07-16 2011-07-15 Superior efficacy of cd37 antibodies in cll blood samples

Publications (2)

Publication Number Publication Date
MX2012013613A true MX2012013613A (es) 2012-12-17
MX341463B MX341463B (es) 2016-08-22

Family

ID=44546328

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012013613A MX341463B (es) 2010-07-16 2011-07-15 Eficacia superior de anticuerpos cd37 en muestras de sangre de cll.

Country Status (14)

Country Link
US (3) US20120189618A1 (es)
EP (2) EP3252077A1 (es)
JP (2) JP2013538790A (es)
KR (1) KR20130100918A (es)
CN (2) CN103003309A (es)
AU (1) AU2011278227B2 (es)
BR (1) BR112013001012A2 (es)
CA (1) CA2799036A1 (es)
CL (1) CL2013000101A1 (es)
EA (1) EA025365B1 (es)
IL (1) IL222775A (es)
MX (1) MX341463B (es)
NZ (2) NZ703225A (es)
WO (1) WO2012007576A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20090499A1 (es) 2007-08-09 2009-05-18 Boehringer Ingelheim Int Anticuerpos anti-cd37
WO2013160396A1 (en) * 2012-04-26 2013-10-31 Boehringer Ingelheim International Gmbh Combination of cd37 antibodies with bendamustine
EP2849784A1 (en) * 2012-05-16 2015-03-25 Boehringer Ingelheim International GmbH Combination of cd37 antibodies with ice (ifosfamide, carboplatin, etoposide)
CN114149511A (zh) * 2015-04-13 2022-03-08 辉瑞公司 靶向b细胞成熟抗原的嵌合抗原受体
US11578115B2 (en) 2017-01-10 2023-02-14 The General Hospital Corporation Chimeric antigen receptors based on alternative signal 1 domains
EP3595721A4 (en) * 2017-03-16 2021-01-06 The General Hospital Corporation CHEMERICAL ANTIGEN RECEPTORS TARGETING CD37
KR20200074915A (ko) 2017-03-31 2020-06-25 젠맵 홀딩 비.브이. 이중특이적 항-cd37 항체, 모노클로날 항-cd37 항체 및 그의 사용 방법
JP7513530B2 (ja) 2018-06-22 2024-07-09 ジェンマブ ホールディング ビー．ブイ． 抗ｃｄ３７抗体および抗ｃｄ２０抗体、組成物、ならびにそれらの使用方法
MA53812A (fr) 2018-10-04 2021-08-11 Genmab Holding B V Compositions pharmaceutiques comprenant des anticorps anti-cd37 bispécifiques
WO2023057583A1 (en) 2021-10-06 2023-04-13 Nordic Nanovector Asa Humanized hh1
WO2023057595A1 (en) 2021-10-06 2023-04-13 Nordic Nanovector Asa Humanized hh1 rew

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
HUE026303T2 (hu) * 2005-07-25 2016-06-28 Emergent Product Dev Seattle B-sejt csökkentés CD37-specifikus és CD20-specifikus kapcsoló molekulák alkalmazásával
US20080279850A1 (en) * 2005-07-25 2008-11-13 Trubion Pharmaceuticals, Inc. B-Cell Reduction Using CD37-Specific and CD20-Specific Binding Molecules
BRPI0814060A2 (pt) * 2007-07-06 2015-01-06 Trubion Pharmaceuticals Inc Peptídeos ligantes tendo um domínio de ligação específico disposto em c-terminal
PE20090499A1 (es) * 2007-08-09 2009-05-18 Boehringer Ingelheim Int Anticuerpos anti-cd37
DK2132228T3 (da) * 2008-04-11 2011-10-10 Emergent Product Dev Seattle CD37-immunterapeutisk middel og kombination med bifunktionelt kemoterapeutisk middel deraf
CN102271708A (zh) * 2008-11-13 2011-12-07 新兴产品开发西雅图有限公司 Cd37免疫治疗联合疗法及其用途

Also Published As

Publication number Publication date
EP3252077A1 (en) 2017-12-06
US20120189618A1 (en) 2012-07-26
AU2011278227A1 (en) 2012-11-15
MX341463B (es) 2016-08-22
JP2017019800A (ja) 2017-01-26
EP2593479A1 (en) 2013-05-22
AU2011278227B2 (en) 2017-03-02
CN103003309A (zh) 2013-03-27
CA2799036A1 (en) 2012-01-19
BR112013001012A2 (pt) 2016-05-24
KR20130100918A (ko) 2013-09-12
WO2012007576A1 (en) 2012-01-19
NZ603161A (en) 2015-02-27
IL222775A0 (en) 2012-12-31
JP2013538790A (ja) 2013-10-17
NZ703225A (en) 2016-11-25
EA201201660A1 (ru) 2013-07-30
US20150266967A1 (en) 2015-09-24
EA025365B1 (ru) 2016-12-30
CL2013000101A1 (es) 2013-12-27
CN105749276A (zh) 2016-07-13
US20130236454A1 (en) 2013-09-12
IL222775A (en) 2017-10-31

Similar Documents

Publication Publication Date Title
MX2012013613A (es) Eficacia superior de anticuerpos cd37 en muestras de sangre de cll.
PH12020550450A1 (en) Certain chemical entities, compositions and methods
NZ574046A (en) Methods and reagents for treatment and diagnosis of vascular disorders and age-related macular degeneration
MX2012011542A (es) Angiogénesis utilizando células madre placentarias.
EA036698B9 (ru) Моноклональное антитело против lif человека и его применение для лечения рака с высоким уровнем lif
PH12017501075A1 (en) Human monoclonal antibody with specificity for dengue virus serotype 1 e protein and uses thereof
BR112014003117A2 (pt) inibidores da corrente funny (if) para uso em um método de tratamento e prevenção de insuficiência cardíaca em felino
UA107115C2 (uk) Тіоацетатні похідіні піридину, композиція на їх основі та їх застосування
MX350010B (es) Inhibidores syk de imidazopiridinas.
JP2013518815A5 (es)
NO20092522L (no) Sammensetninger og fremgangsmater for a behandle kreft med cupredoxiner og CPG rikt DNA
WO2012142301A3 (en) Methods of determining a treatment protocol for and/or a prognosis of a patients recovery from a brain injury
TN2014000337A1 (en) Cancer patient selection for administration of wnt signaling inhibitors using rnf43 mutation status
GB2496794A (en) Combination pharmaceutical composition and methods of treating and methods of treating functional diseases or conditions of gastrointestinal tract
WO2012142300A3 (en) Methods of determining a treatment protocol for and/or a prognosis of a patient's recovery from a brain injury resulting from a hypoxic event
EA201390335A1 (ru) Введение лоркасерина индивидуумам с почечной недостаточностью
MX2010010799A (es) Metodo de diagnostico, prevencion y tratamiento de las enfermedades de la masa osea.
WO2013106766A3 (en) THERAPEUTIC INDICATIONS OF miR-1291
UA116615C2 (uk) Застосування ондансетрону у лікуванні хвороби чи розладу, пов'язаних з алкоголем
NZ702666A (en) A method of weight reduction
Patel et al. miR-489 function as tumor suppressor miRNA by targeting HER2 in HER2-positive breast cancer
Mendell et al. GO 24: Eteplirsen in Duchenne Muscular Dystrophy (DMD): 3 year update on Six-Minute Walk Test (6MWT) and Safety
Sari Arthralgia and toxicoderma: 2 case reports
McBride Optimal Age for Colonoscopy May Be Based on Gender.
Nair et al. Allogeneic Haematopoietic Stem Cell Transplantation: 53 Army Hospital Experience

Legal Events

Date Code Title Description
FG Grant or registration